Phil Nadeau
Stock Analyst at TD Cowen
(0.89)
# 1,710
Out of 4,829 analysts
22
Total ratings
20%
Success rate
-5.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Buy | n/a | $6.09 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $58.97 | +10.23% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $124.40 | +121.06% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $61.37 | +95.54% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $439.37 | +13.80% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $18.99 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $40.18 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.35 | - | 1 | Nov 23, 2021 | |
| ANNX Annexon | Initiates: Outperform | n/a | $1.77 | - | 1 | Aug 18, 2020 | |
| KZR Kezar Life Sciences | Initiates: Outperform | n/a | $4.23 | - | 1 | Jul 16, 2018 |
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $6.09
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $58.97
Upside: +10.23%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $124.40
Upside: +121.06%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $61.37
Upside: +95.54%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $439.37
Upside: +13.80%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $18.99
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $40.18
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.35
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.77
Upside: -
Kezar Life Sciences
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $4.23
Upside: -